Litcius/Paper detail

Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Rohit Loomba, Erin E. Morgan, Keyvan Yousefi, Dan Li, Richard S. Geary, Sanjay Bhanot, Naim Alkhouri

2025The Lancet23 citationsDOI

Topics & Concepts

SteatohepatitisPlaceboMedicineInternal medicineNonalcoholic steatohepatitisDouble blindGastroenterologyFatty liverDiseasePathologyAlternative medicineNonalcoholic fatty liver diseaseLiver Disease Diagnosis and TreatmentLipid metabolism and biosynthesisDiabetes, Cardiovascular Risks, and Lipoproteins
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Litcius